Day: May 13, 2022

All amounts in U.S. dollars unless otherwise stated TORONTO, May 13, 2022 (GLOBE NEWSWIRE) — Onex Corporation (TSX: ONEX) today announced its financial results for the first quarter ended March 31, 2022 and an update on matters following quarter-end. “Onex had a solid start to the year.  Our businesses continue to execute, and the fundamentals of our firm are strong.  Despite a challenging backdrop, our portfolio is performing well, reflecting the diversification and resiliency of our investments overall,” said Gerry Schwartz, Chairman and Chief Executive Officer of Onex. “We remain focused on delivering on our plan to grow our asset management business and increase long-term value for shareholders.” Financial Results(unaudited)($ millions except per share amounts) Three Months Ended March 31, 2022   Three Months Ended March...

Topline readout of Phase 2 AML trial Group 2 active disease anticipated in Q2 2022 Company plans to file INDs in lymphoma and pancreatic cancer by year end, with clinical trials to be initiated in 2023 HOUSTON, May 13, 2022 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the first quarter ended March 31, 2022. “2022 has already been an exciting year for Marker as we reported encouraging initial results from the six-patient safety lead-in portion of our Phase 2 AML trial—including elimination of MRD in one MRD positive patient—and announced plans for Company-sponsored...

New data on lead oncology programs aumolertinib and sugemalimab to be presented at the 2022 ASCO Annual Meeting, including pre-specified interim overall survival (OS) data from the Phase 3 GEMSTONE-302 study of sugemalimab plus chemotherapy in first-line Stage IV NSCLC Continue to expect first regulatory submissions for aumolertinib and sugemalimab ex-U.S. in 2H 2022; constructive conversations with the FDA are ongoing to gain greater clarity on the regulatory path forward in the U.S. Continue to advance the Global Buyers Club; first conversion of a memorandum of understanding (MOU) to a pre-commercialization agreement EQRx to host conference call and webcast today at 8:00 a.m. ETCAMBRIDGE, Mass., May 13, 2022 (GLOBE NEWSWIRE) — EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering...

MIRAMAR, Fla., May 13, 2022 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2022. “We continue to successfully execute our clinical development strategy which is based on our unique approach toward inflammaging,” stated Hing C. Wong, Founder and CEO of HCW Biologics Inc. “HCW Biologics is developing immunotherapeutics that do not treat a single indication or symptom. Our approach is to treat a patient systemically to remove the underlying problems causing a condition.” Dr. Wong continued, “Our...